Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 6/2010

01-05-2010 | Short Communication

Population pharmacokinetic study of a test dose oral busulfan in Japanese adult patients undergoing hematopoietic stem cell transplantation

Authors: Yasushi Takamatsu, Noriaki Sasaki, Kentaro Ogata, Eiji Yukawa, Shiro Jimi, Shuuji Hara, Kazuo Tamura

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2010

Login to get access

Abstract

Purpose

The aim of this study is to determine the population pharmacokinetics of oral busulfan in Japanese adults.

Methods

We previously underwent a clinical trial involving the dose adjustment of oral busulfan depending on the individual pharmacokinetics using a test dose in hematopoietic stem cell transplantation recipients. Seventy-one Japanese patients aged from 16 to 67 years were enrolled. After taking oral busulfan 0.5 mg/kg as a test dose, blood samples were collected at five time points from each patient. Busulfan concentrations were measured by high-performance liquid chromatography, and the individual parameters were estimated by using the nonlinear mixed effects model computer program. A one-compartment model with first-order absorption was sufficient to describe the concentration–time profile.

Results

The final pharmacokinetic parameter were the clearance (CL/F) = 0.153 L/h/kg, distribution volume (Vd/F) = 0.695 L/kg, and absorption rate constant (ka) = 2.39 h−1. The inter-individual variabilities in CL/F, Vd/F and ka were 25.9, 26.2, and 111.8%, respectively, and the residual variability was 12.1% as the coefficient of variation.

Conclusion

We developed a population pharmacokinetic model of oral busulfan in Japanese adults. The final population model was implemented into the program excel, leading to an easy and proper therapeutic monitoring of oral BU by using small number of samples.
Literature
1.
go back to reference Hassan M, Ljungman P, Bolme P, Ringdén O, Syrůcková Z, Békàssy A, Starý J, Wallin I, Kållberg N (1994) Busulfan bioavailability. Blood 84:2144–2150PubMed Hassan M, Ljungman P, Bolme P, Ringdén O, Syrůcková Z, Békàssy A, Starý J, Wallin I, Kållberg N (1994) Busulfan bioavailability. Blood 84:2144–2150PubMed
2.
go back to reference Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE, York RC, Lin LS, Devine SM, Geller RB, Heffner LT, Hillyer CD, Holland HK, Winton EF, Saral R (1996) Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 17:225–230PubMed Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE, York RC, Lin LS, Devine SM, Geller RB, Heffner LT, Hillyer CD, Holland HK, Winton EF, Saral R (1996) Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 17:225–230PubMed
3.
go back to reference Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI, Soll E, Anasetti C, Bowden R, Bryant E, Chauncey T, Deeg HJ, Doney KC, Flowers M, Gooley T, Hansen JA, Martin PJ, McDonald GB, Nash R, Petersdorf EW, Sanders JE, Schoch G, Stewart P, Storb R, Sullivan KM, Thomas ED, Witherspoon RP, Appelbaum FR (1997) Marrow transplantation for chronic myeloid leukemia : the influence of plasma busulfan levels on the outcome of transplantation. Blood 89:3055–3060PubMed Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI, Soll E, Anasetti C, Bowden R, Bryant E, Chauncey T, Deeg HJ, Doney KC, Flowers M, Gooley T, Hansen JA, Martin PJ, McDonald GB, Nash R, Petersdorf EW, Sanders JE, Schoch G, Stewart P, Storb R, Sullivan KM, Thomas ED, Witherspoon RP, Appelbaum FR (1997) Marrow transplantation for chronic myeloid leukemia : the influence of plasma busulfan levels on the outcome of transplantation. Blood 89:3055–3060PubMed
4.
go back to reference Bolinger AM, Zangwill AB, Slattery JT, Glidden D, DeSantes K, Heyn L, Risler LJ, Bostrom B, Cowan MJ (2000) An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease. Bone Marrow Transplant 25:925–930CrossRefPubMed Bolinger AM, Zangwill AB, Slattery JT, Glidden D, DeSantes K, Heyn L, Risler LJ, Bostrom B, Cowan MJ (2000) An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease. Bone Marrow Transplant 25:925–930CrossRefPubMed
5.
go back to reference McCune JS, Gooley T, Gibbs JP, Sanders JE, Petersdorf EW, Appelbaum FR, Anasetti C, Risler L, Sultan D, Slattery JT (2002) Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 30:167–173CrossRefPubMed McCune JS, Gooley T, Gibbs JP, Sanders JE, Petersdorf EW, Appelbaum FR, Anasetti C, Risler L, Sultan D, Slattery JT (2002) Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 30:167–173CrossRefPubMed
6.
go back to reference Takamatsu Y, Ogata K, Yamauchi K, Hara S, Kamimura T, Hayashi S, Suzumiya J, Tamura K (2005) An evaluation of busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. Jpn J Clin Oncol 35:400–403CrossRefPubMed Takamatsu Y, Ogata K, Yamauchi K, Hara S, Kamimura T, Hayashi S, Suzumiya J, Tamura K (2005) An evaluation of busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. Jpn J Clin Oncol 35:400–403CrossRefPubMed
7.
go back to reference Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, Hansen JA, Kiem HP, Martin PJ, Petersdorf E, Radich JP, Sanders JE, Shulman HM, Warren EH, Witherspoon RP, Bryant EM, Chauncey TR, Getzendaner L, Storb R, Appelbaum FR (2002) Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100:1201–1207CrossRefPubMed Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, Hansen JA, Kiem HP, Martin PJ, Petersdorf E, Radich JP, Sanders JE, Shulman HM, Warren EH, Witherspoon RP, Bryant EM, Chauncey TR, Getzendaner L, Storb R, Appelbaum FR (2002) Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100:1201–1207CrossRefPubMed
8.
go back to reference Radich JP, Gooley T, Bensinger W, Chauncey T, Clift R, Flowers M, Martin P, Slattery J, Sultan D, Appelbaum FR (2003) HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 102:31–35CrossRefPubMed Radich JP, Gooley T, Bensinger W, Chauncey T, Clift R, Flowers M, Martin P, Slattery J, Sultan D, Appelbaum FR (2003) HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 102:31–35CrossRefPubMed
9.
go back to reference Takamatsu Y, Sasaki N, Eto T, Nagafuji K, Abe Y, Choi I, Ogata K, Hara S, Suzumiya J, Tamura K (2007) Individual dose adjustment of oral busulfan using a test dose in hematopoietic stem cell transplantation. Int J Hematol 86:261–268CrossRefPubMed Takamatsu Y, Sasaki N, Eto T, Nagafuji K, Abe Y, Choi I, Ogata K, Hara S, Suzumiya J, Tamura K (2007) Individual dose adjustment of oral busulfan using a test dose in hematopoietic stem cell transplantation. Int J Hematol 86:261–268CrossRefPubMed
10.
go back to reference Sandström M, Karlsson MO, Ljungman P, Hassan Z, Jonsson EN, Nilsson C, Ringden O, Oberg G, Bekassy A, Hassan M (2001) Population pharmacokinetic analysis resulting in a tool for dose individualization of busulfan in bone marrow transplantation recipients. Bone Marrow Transplant 28:657–664CrossRefPubMed Sandström M, Karlsson MO, Ljungman P, Hassan Z, Jonsson EN, Nilsson C, Ringden O, Oberg G, Bekassy A, Hassan M (2001) Population pharmacokinetic analysis resulting in a tool for dose individualization of busulfan in bone marrow transplantation recipients. Bone Marrow Transplant 28:657–664CrossRefPubMed
11.
go back to reference Gibbs JP, Czerwinski M, Slattery JT (1996) Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione S-transferases. Cancer Res 56:3678–3681PubMed Gibbs JP, Czerwinski M, Slattery JT (1996) Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione S-transferases. Cancer Res 56:3678–3681PubMed
12.
go back to reference Srivastava A, Poonkuzhali B, Shaji RV, George B, Mathews V, Chandy M, Krishnamoorthy R (2004) Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood 104:1574–1577CrossRefPubMed Srivastava A, Poonkuzhali B, Shaji RV, George B, Mathews V, Chandy M, Krishnamoorthy R (2004) Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood 104:1574–1577CrossRefPubMed
13.
go back to reference Arruda VR, Grignolli CE, Gonçalves MS, Soares MC, Menezes R, Saad ST, Costa FF (1998) Prevalence of homozygosity for the deleted alleles of glutathione S-transferase mu (GSTM1) and theta (GSTT1) among distinct ethnic groups from Brazil: relevance to environmental carcinogenesis? Clin Genet 54:210–214PubMed Arruda VR, Grignolli CE, Gonçalves MS, Soares MC, Menezes R, Saad ST, Costa FF (1998) Prevalence of homozygosity for the deleted alleles of glutathione S-transferase mu (GSTM1) and theta (GSTT1) among distinct ethnic groups from Brazil: relevance to environmental carcinogenesis? Clin Genet 54:210–214PubMed
14.
go back to reference Kusama M, Kubota T, Matsukura Y, Matsuno K, Ogawa S, Kanda Y, Iga T (2006) Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan. Clinica Chimica Acta 368:93–98CrossRef Kusama M, Kubota T, Matsukura Y, Matsuno K, Ogawa S, Kanda Y, Iga T (2006) Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan. Clinica Chimica Acta 368:93–98CrossRef
15.
go back to reference Coles BF, Morel F, Rauch C, Huber WW, Yang M, Teitel CH, Green B, Lang NP, Kadlubar FF (2001) Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression. Pharmacogenetics 11:663–669CrossRefPubMed Coles BF, Morel F, Rauch C, Huber WW, Yang M, Teitel CH, Green B, Lang NP, Kadlubar FF (2001) Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression. Pharmacogenetics 11:663–669CrossRefPubMed
16.
go back to reference Hara S, Tsuchie M, Tsujioka R, Kimura M, Fujii M, Kuroda T, Ono N (2000) High-performance liquid chromatographic quantification of busulfan in human serum after fluorescence derivetization by 2-Naphthalenethiol. Anal Sci 16:287–291CrossRef Hara S, Tsuchie M, Tsujioka R, Kimura M, Fujii M, Kuroda T, Ono N (2000) High-performance liquid chromatographic quantification of busulfan in human serum after fluorescence derivetization by 2-Naphthalenethiol. Anal Sci 16:287–291CrossRef
17.
go back to reference Sheiner LB, Beal ST (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503–512CrossRefPubMed Sheiner LB, Beal ST (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503–512CrossRefPubMed
18.
go back to reference McCune JS, Gibbs JP, Slattery JT (2000) Plasma concentration monitoring of busulfan: does it improve clinical outcome? Clin Pharmacokinet 39:155–165CrossRefPubMed McCune JS, Gibbs JP, Slattery JT (2000) Plasma concentration monitoring of busulfan: does it improve clinical outcome? Clin Pharmacokinet 39:155–165CrossRefPubMed
19.
go back to reference Nakamura H, Sato T, Okada K, Miura G, Ariyoshi N, Nakazawa K, Kitada M (2008) Population pharmacokinetics of oral busulfan in young Japanese children before hematopoietic stem cell transplantation. Ther Drug Monit 30:75–83CrossRefPubMed Nakamura H, Sato T, Okada K, Miura G, Ariyoshi N, Nakazawa K, Kitada M (2008) Population pharmacokinetics of oral busulfan in young Japanese children before hematopoietic stem cell transplantation. Ther Drug Monit 30:75–83CrossRefPubMed
20.
go back to reference Takama H, Tanaka H, Nakashima D, Ueda R, Takaue Y (2006) Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell plantation. Bone Marrow Transplant 37:345–351CrossRefPubMed Takama H, Tanaka H, Nakashima D, Ueda R, Takaue Y (2006) Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell plantation. Bone Marrow Transplant 37:345–351CrossRefPubMed
Metadata
Title
Population pharmacokinetic study of a test dose oral busulfan in Japanese adult patients undergoing hematopoietic stem cell transplantation
Authors
Yasushi Takamatsu
Noriaki Sasaki
Kentaro Ogata
Eiji Yukawa
Shiro Jimi
Shuuji Hara
Kazuo Tamura
Publication date
01-05-2010
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 6/2010
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-010-1263-7

Other articles of this Issue 6/2010

Cancer Chemotherapy and Pharmacology 6/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine